Zimmer Biomet Chairman, President and CEO Ivan Tornos Joins OREF Board of Trustees
Mr. Tornos joined Zimmer Biomet in 2018 as Group President, Orthopedics. Prior to his appointment as President and Chief Executive Officer in 2023, he held the positions of Group President, Global Businesses and the Americas, and Chief Operating Officer with responsibility for overseeing all global businesses at Zimmer Biomet. He was elected Chairman of the Board of Directors of Zimmer Biomet, a global leader in musculoskeletal health, in May of 2025.
OREF Board President, Joshua J. Jacobs, MD, stated, "On behalf of the entire board, I am delighted to welcome Ivan to OREF. Our two organizations have a long history of collaboration and a shared commitment to improving patient care and outcomes. Ivan's presence on the OREF board will bring heightened visibility to our mission and to the need for more research funding. His service to OREF and the financial support of Zimmer Biomet underscore his commitment to improving the health of our communities here in the U.S. and throughout the world."
"I am thrilled to be joining the OREF board. Now more than ever, it's important we move with a sense of urgency and deep purpose to ensure that musculoskeletal research advances at a much faster pace and delivers even bolder solutions. There are countless patients currently waiting on the sidelines who could benefit from the meaningful work that we will do together, and I'm committed to doing all I can to reduce the current gaps in this area," said Ivan Tornos.
The growing burden of MSK conditions in the United States is well documented with MSK-related diseases and injuries affecting more than half of the adult population and imposing an estimated economic burden of $980 billion annually.1 Despite the outsized impact of MSK diseases on quality of life and the U.S. economy, funding for MSK conditions is disproportionately low when comparing the physical and economic burden of various diseases. OREF is a leading voice in advocating for increased MSK research funding and strongly believes that the nation's healthcare will not improve unless and until MSK research funding becomes a national priority.
OREF grantees' success in securing additional funding from the NIH and other government entities is unparalleled within the MSK research community. Research published in JBJS demonstrates that OREF grant recipients are more likely to receive subsequent NIH funding compared to other applicants (23.5 percent vs. 20.6 percent), with Career Development Grant recipients achieving a 48.4 percent success rate.2 Given the limited availability of MSK research funds, investing in a reputable independent source with a proven return on investment is essential. OREF's collaboration with more than 60 MSK-related organizations is a key factor in its success in funding significant and impactful research that improves clinical practice and patient outcomes.
About OREF
An independent 501(c)3 nonprofit, OREF strives to improve clinical care and patient outcomes by advancing innovative research, developing new investigators, and uniting the orthopaedic community in promoting musculoskeletal health. The Foundation raises funds to support research on diseases and injuries of bones, nerves, muscles, and tendons and to enhance clinical care leading to improved health, increased activity, and a better quality of life for patients. For more information, visit oref.org or follow OREF on X and LinkedIn.
1United States Bone and Joint Initiative: The Burden of Musculoskeletal Diseases in the United States (BMUS), Third Edition, 2014. Rosemont, IL. Available at https://bmus.latticegroup.com/fourth-edition/if0/healthcare-utilization-and-economic-cost
2Li, Alan K. BS1,a; Kendal, Joseph K. MD, MSc2; Hamad, Christopher D. MD2; Peterson, Nicholas V. MD2; Asachi, Parsa BA1; Taylor, Jeremiah M. BS1; Le, Michael M. MD1; Lloyd, Trevor S. BS1; Wessel, Lauren E. MD2; Bernthal, Nicholas M. MD2. Identifying Predictors of Successful Conversion from OREF Grants to Extramural Federal Funding Among Orthopaedic Surgeons. The Journal of Bone and Joint Surgery 107(1):p 96-103, January 1, 2025. DOI: 10.2106/JBJS.24.0064
View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-chairman-president-and-ceo-ivan-tornos-joins-oref-board-of-trustees-302466210.html
SOURCE Orthopaedic Research and Education Foundation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
an hour ago
- The Hill
Luna says lawmakers have evidence of ‘interdimensional beings'
Rep. Anna Paulina Luna (R-Fla.) said during a Wednesday podcast episode with Joe Rogan that lawmakers have seen evidence of 'interdimensional beings.' 'I think that they can actually operate through the time spaces that we currently have,' Luna said during the podcast. 'And that's not something that I came up with on my own. That's based on stuff that we've seen. That's based on information that we've been told,' she added. In February, Luna and Rep. James Comer (R-Ky.) sent letters to Secretary of State Marco Rubio, Secretary of Defense Pete Hegseth and CIA Director John Ratcliffe requesting a briefing on all unidentified anomalous phenomena or UAP-related records in their possession, with the ultimate goal of 'deliver[ing] transparency to the American people.' She says through investigations, she's discovered otherworldly information. 'Based on testimony that would be based on witnesses that have come forward. But what I can tell you is just we're told that they were that, they've seen things,' Luna told Rogan. 'And what I can tell you without getting into classified conversations is that there have been incidences that I believe were very credible people have reported that there have been movement outside of time and space,' she continued. Luna said she's never seen a portal or a spaceship but was searching for documentation that could lead to more evidence of life beyond humans.
UPI
8 hours ago
- UPI
NIH study links cigarette cessation with drug, alcohol addiction recovery
On Wednesday, scientists at the National Institutes of Health in Bethesda, Md. (pictured in March), said fresh data in its nearly 15-year-old ongoing PATH study with the FDA is suggesting longer-term remission from drug or alcohol addiction is more likely if a person also quits cigarettes at the same time. File Photo by Annabelle Gordon/UPI | License Photo Aug. 13 (UPI) -- A new federal study is linking the ability to quit smoking with longer-term success from the grip of drug or alcohol addiction, as well. Scientists at the National Institutes of Health on Wednesday said that fresh data in its nearly 15-year-old ongoing PATH study with the U.S. Food and Drug Administration is suggesting that sustained remission from drug or alcohol addiction is more likely to be achieved if a person also quits cigarettes at the same time versus separately. The PATH study, or Population Assessment of Tobacco and Health Study, has been ongoing for more than a decade in an attempt to better understand the health effects of smoking. "It underscores the importance of addressing different addictions together, rather than in isolation," Dr. Nora Volkow director of NIH's National Institute on Drug Abuse, said in a statement. Health officials pointed out that people in addiction also have a higher likelihood of being addicted to nicotine. The longitudinal NIH analysis showed a 42% greater odd of going from a "current" to "former" smoker if a person is already working in a recovery stage from a non-tobacco vice. Volkow added that NIH national sampling is "strong evidence" that quitting cigarette smoking "predicts improved recovery from other substance use disorders." The federally funded PATH study analyzed more than 2,650 participants age 18 or older with a history of substance abuse but with a change in recovery over a four-year period. As part of the study, NIH researchers asked annual questions of participants concerning smoking habits and use of other items. "Although the health benefits of quitting smoking are well-known, smoking cessation has not been seen as a high priority in drug addiction treatment programs," stated Dr. Wilson Compton, deputy director of NIDA and the study's senior author. The study's authors highlighted it's uniqueness but noted it was only suggestive in nature, that prior studies had utilized addiction-specific data out of U.S. drug and alcohol treatment centers that "could not adequately test for an association" with cigarette smoking. Compton said the findings "bolster support for including smoking cessation as part of addiction treatment." Officials at NIH said its researchers have an "increasing confidence" in the belief the new finding are "generalizable to the millions of adults" in the throes of alcohol or drug addiction in the United States. However, they added that further research is needed to "definitively establish" a causal connection.
Atlantic
9 hours ago
- Atlantic
COVID Revenge Is Supercharging the Anti-Vaccine Agenda
Four and a half years ago, fresh off the success of Operation Warp Speed, mRNA vaccines were widely considered—as President Donald Trump said in December 2020 —a 'medical miracle.' Last week, the United States government decidedly reversed that stance when Secretary of Health and Human Services Robert F. Kennedy Jr. canceled nearly half a billion dollars' worth of grants and contracts for mRNA-vaccine research. With Kennedy leading HHS, this about-face is easy to parse as yet another anti-vaccine move. But the assault on mRNA is also proof of another kind of animus: the COVID-revenge campaign that top officials in this administration have been pursuing for months, attacking the policies, technologies, and people that defined the U.S.'s pandemic response. As the immediacy of the COVID crisis receded, public anger about the American response to it took deeper root—perhaps most prominently among some critics who are now Trump appointees. That acrimony has become an essential tool in Kennedy's efforts to undermine vaccines. 'It is leverage,' Dorit Reiss, a vaccine-law expert at UC Law San Francisco, told me. 'It is a way to justify doing things that he wouldn't be able to get away with otherwise.' COVID revenge has defined the second Trump administration's health policy from the beginning. Kennedy and his allies have ousted prominent HHS officials who played key roles in the development of COVID policy, as well as scientists at the National Institutes of Health, including close colleagues of Anthony Fauci, the former director of the National Institute of Allergy and Infectious Diseases (and, according to Trump, an idiot and a 'disaster'). In June, Kennedy dismissed every member of the CDC Advisory Committee on Immunization Practices (ACIP), which has helped shape COVID-vaccine recommendations, and handpicked replacements for them. HHS and ACIP are now stacked with COVID contrarians who have repeatedly criticized COVID policies and minimized the benefits of vaccines. Under pressure from Trump officials, the NIH has terminated funding for hundreds of COVID-related grants. The president and his appointees have espoused the highly disputed notion that COVID began as a leak from 'an unsafe lab in Wuhan, China'—and cited the NIH's funding of related research as a reason to restrict federal agencies' independent grant-awarding powers. This administration is rapidly rewriting the narrative of COVID vaccines as well. In an early executive order, Trump called for an end to COVID-19-vaccine mandates in schools, even though few remained; earlier this month, HHS rolled back a Biden-era policy that financially rewarded hospitals for reporting staff-vaccination rates, describing the policy as ' coercive.' The FDA has made it harder for manufacturers to bring new COVID shots to market, narrowed who can get the Novavax shot, and approved the Moderna COVID-19 vaccines for only a limited group of children, over the objections of agency experts. For its part, the CDC softened its COVID-shot guidance for pregnant people and children, after Kennedy—who has described the shots as 'the deadliest vaccine ever made'—tried to unilaterally remove it. Experts told me they fear that what access remains to the shots for children and adults could still be abolished; so could COVID-vaccine manufacturers' current protection from liability. (Andrew Nixon, an HHS spokesperson, said in an email that the department would not comment on potential regulatory changes.) The latest assault against mRNA vaccines, experts told me, is difficult to disentangle from the administration's pushback on COVID shots—which, because of the pandemic, the public now views as synonymous with the technology, Jennifer Nuzzo, the director of the Pandemic Center at Brown University School of Public Health, told me. Kennedy justified the mRNA cuts by suggesting—in contrast to a wealth of evidence—that the vaccines' risks outweigh their benefits, and that they 'fail to protect effectively against upper respiratory infections like COVID and flu.' And he insisted, without proof, that mRNA vaccines prolong pandemics. Meanwhile, NIH Director Jay Bhattacharya argued that the cancellations were driven by a lack of public trust in the technology itself. In May, the Trump administration also pulled more than $700 million in funds from Moderna that had initially been awarded to develop mRNA-based flu vaccines. The mRNA funding terminated so far came from HHS's Biomedical Advanced Research and Development Authority; multiple NIH officials told me that they anticipate that similar grant cuts will follow at their agency. (In an email, Kush Desai, a spokesperson for the White House, defended the administration's decision as a way to prioritize funding with 'the most untapped potential'; Nixon echoed that sentiment, casting the decision as 'a necessary pivot in how we steward public health innovations in vaccines.') COVID is a politically convenient entryway to broader anti-vaccine sentiment. COVID shots are among the U.S.'s most politicized vaccines, and many Republicans have, since the outbreak's early days, been skeptical of COVID-mitigation policies. Although most Americans remain supportive of vaccines on the whole, most Republicans—and many Democrats—say they're no longer keen on getting more COVID shots. 'People trust the COVID vaccines less,' Nuzzo told me, which makes it easy for the administration's vaccine opponents to use attacks on those vaccines as purchase for broader assaults. For all their COVID-centric hype, mRNA vaccines have long been under development for many unrelated diseases. And experts now worry that the blockades currently in place for certain types of mRNA vaccines could soon extend to other, similar technologies, including mRNA-based therapies in development for cancer and genetic disease, which might not make it through the approval process at Kennedy's FDA. (Nixon said HHS would continue to invest in mRNA research for cancer and other complex diseases.) Casting doubt on COVID shots makes other vaccines that have been vetted in the same way—and found to be safe and effective, based on high-quality data—look dubious. 'Once you establish that it's okay to override something for COVID,' Reiss told me, 'it's much easier to say, 'Well, now we're going to unrecommend MMR.'' (Kennedy's ACIP plans to review the entire childhood-immunization schedule and assess its cumulative effects.) Plenty of other avenues remain for Kennedy to play on COVID discontent—fear of the shots' side effects, distaste for mandates, declining trust in public health and medical experts —to pull back the government's support for vaccination. He has announced, for instance, his intention to reform the Vaccine Injury Compensation Program, which helps protect manufacturers from lawsuits over illegitimate claims about a vaccine's health effects, and his plans to find 'ways to enlarge that program so that COVID-vaccine-injured people can be compensated.' Some of the experts I spoke with fear that the FDA's Vaccines and Related Biological Products Advisory Committee—the agency's rough equivalent of ACIP—could be remade in Kennedy's vision. The administration has also been very willing to rescind federal funding from universities in order to forward its own ideas: Kennedy could, perhaps, threaten to withhold money from universities that require any vaccines for students. Kennedy has also insisted that 'we need to stop trusting the experts'—that Americans, for instance, shouldn't have been discouraged from doing their own research during the pandemic. He could use COVID as an excuse to make that maxim Americans' reality: Many public-health and infectious-disease-focused professional societies rely on at least some degree of federal funding, Nirav D. Shah, a former principal deputy director of the CDC, told me. Stripping those resources would be 'a way to cut their legs off'—or, at the very least, would further delegitimize those expert bodies in the public eye. Kennedy has already barred representatives from professional societies, including the American Academy of Pediatrics and the Infectious Diseases Society of America, from participating in ACIP subcommittees after those two societies and others collectively sued HHS over its shifts in COVID policy. The public fight between medicine and government is now accelerating the nation onto a path where advice diverges over not just COVID shots but vaccines generally. (When asked about how COVID resentment was guiding the administration's decisions, Desai said that the media had politicized science to push for pandemic-era mandates and that The Atlantic 'continues to fundamentally misunderstand how the Trump administration is reversing this COVID era politicization of HHS.') The coronavirus pandemic began during the first Trump presidency; now its legacy is being exploited by a second one. Had the pandemic never happened, Kennedy would likely still be attacking vaccines, maybe even from the same position of power he currently commands. But without the lightning rod of COVID, Kennedy's attacks would be less effective. Already, one clear consequence of the Trump administration's anti-COVID campaign is that it will leave the nation less knowledgeable about and less prepared against all infectious diseases, Gregory Poland, a vaccinologist and the president of Atria Research Institute, told me. That might be the Trump administration's ultimate act of revenge. No matter who is in charge when the U.S. meets its next crisis, those leaders may be forced into a corner carved out by Trump and Kennedy—one from which the country must fight disease without adequate vaccination, research, or public-health expertise. This current administration will have left the nation with few other options.
